|
Mean (SD) / Median (IQR) |
Missing |
Mean (SD) / Median (IQR) |
Missing |
Mean (SD) / Median (IQR) |
Missing |
Mean (SD) / Median (IQR) |
Missing |
A vs B |
A vs C |
A vs D |
Annualised rate of exacerbations, median (IQR) |
4 (5) † |
2 |
5 (2) † |
1 |
4 (5) † |
1 |
5 (3) ‡ |
32 |
0.526 |
0.864 |
0.978 |
Annualised rate of AHE, median (IQR) |
1 (3) † |
1 |
0 (2) † |
8 |
0 (1) † |
2 |
0 (1) ‡ |
1 |
0.095 |
0.002 |
0.028 |
Maximum Eos count in the past year, median (IQR) - cells/µL |
400 (400) † |
2 |
200 (400) † |
7 |
500 (500) † |
0 |
200 (300) ‡ |
49 |
0.005 |
0.178 |
<0.001 |
ACQ6, median (IQR) |
3.67 (1.26) § |
6 |
3 (1.83) § |
20 |
2.33
(2.27) § |
2 |
3 (1.8) ‡ |
11 |
0.036 |
<0.001 |
0.017 |
FENO, median (IQR) - ppb |
22 (59.6) § |
4 |
29.5 (37) § |
24 |
37 (46.5) § |
2 |
16.85 (24.65) ‡ |
50 |
0.514 |
0.129 |
0.383 |
Clinic FEV1 %, mean (SD) |
61.64 (21.75) § |
1 |
68.13 (20.49) § |
6 |
67% (20.1) § |
1 |
76.78 (23.37) ‡ |
57 |
0.483 |
0.909 |
0.003 |
BMI, median (IQR) -kgm-2 ‡ |
30.6 (15.9) |
0 |
30.36 (5.99) |
0 |
29.1 (11.5) |
0 |
30.8 (10.8) |
3 |
0.194 |
0.160 |
0.469 |
Age at asthma diagnosis, median (IQR) - y ‡ |
12 (31) |
0 |
11
(25.5) |
3 |
33.5 (40.5) |
1 |
20 (35) |
9 |
0.627 |
0.032 |
0.355 |
Age, median (IQR) - y |
54 (28) |
0 |
53 (20.5) |
0 |
61 (19) |
0 |
54.5 (25) |
0 |
0.871 |
0.110 |
0.997 |
|
Percentage (N) |
Missing |
Percentage (N) |
Missing |
Percentage (N) |
Missing |
Percentage (N) |
Missing |
A vs B |
A vs C |
A vs
D |
Multiple (>1) AHE, Yes |
48% (12) † |
2 |
27.4%
(23) † |
8 |
9.8% (4) † |
2 |
24.3% (43) ‡ |
5 |
0.053 |
0.001 |
<0.001 |
On maintenance OCS, Yes |
66.7% (18) § |
0 |
46.7% (43) § |
0 |
69.8% (30) § |
0 |
30.6% (53) ‡ |
1 |
0.069 |
0.797 |
0.013 |
Adult-onset asthma, Yes
|
38.5% (10) |
0 |
39.3%
(35) |
1 |
61.9% (26) |
1 |
52.7% (89) |
9 |
1.000 |
0.060 |
0.178 |
Sex, Male |
33.3% (9) |
0 |
35.9% (33) |
0 |
58.1% (25) |
0 |
29.8% (53) |
0 |
1.000 |
0.043 |
0.822 |
Ethnicity, White |
92.6% (25) |
0 |
89.1% (82) |
0 |
90.7%
(39) |
0 |
94.9% (169) |
0 |
0.732 |
1.000 |
0.642 |
Rhinitis, Ever ‡ |
80.8% (21) |
1 |
73.0% (54) |
22 |
68.3%
(28) |
2 |
60.1% (95) |
10 |
0.430 |
0.262 |
0.043 |
GORD, Ever ‡ |
73.1% (19) |
1 |
64.1% (59) |
0 |
61.9% (26) |
1 |
65.3% (111) |
8 |
0.485 |
0.344 |
0.434 |
Smoking, Ever ‡ |
51.9% (14) |
0 |
43.5% (40) |
0 |
53.5%
(23) |
0 |
47.5% (84) |
1 |
0.442 |
0.894 |
0.670 |
Atopy (SPT /sIgE positive) ‡ |
74.0% (20) |
0 |
100% (92) |
0 |
51.2% (22) |
0 |
52.8% (94) |
0 |
<0.001 |
0.057 |
0.038 |
Obesity (BMI≥30kgm-2), Ever ‡ |
55.6% (15) |
0 |
50.0% (46) |
0 |
41.9% (18) |
0 |
52.6% (92) |
3 |
0.612 |
0.190 |
0.772 |
ICU admission for asthma, Ever ‡ |
33.3% (9) |
0 |
26.4% (24) |
1 |
37.2% (16) |
0 |
32.6% (58) |
0 |
0.479 |
0.802 |
1.000 |
Intubated for Asthma, Ever ‡ |
18.5% (5) |
0 |
14.3% (13) |
1 |
9.3% (4) |
0 |
17.4% (31) |
0 |
0.591 |
0.292 |
1.000 |
Dysfunctional breathing, Ever ‡ |
59.3% (16) |
0 |
48.8% (42) |
6 |
31.7% (13) |
2 |
55.1% (92) |
11 |
0.345 |
0.025 |
0.686 |
ILO, Ever ‡ |
25.9% (7) |
0 |
17.5% (14) |
12 |
7.7% (3) |
4 |
13.2% (21) |
19 |
0.340 |
0.077 |
0.140 |
Depression, Ever ‡ |
48% (12) |
2 |
30.4% (24) |
13 |
19.1%
(8) |
1 |
42.8% (68) |
19 |
0.107 |
0.012 |
0.624 |
Anxiety, Ever ‡ |
50% (13) |
1 |
26.6% (21) |
13 |
20.0% (8) |
3 |
38.0% (60) |
19 |
0.027 |
0.011 |
0.245 |
Bronchiectasis, Ever ‡ |
18.5% (5) |
0 |
14.4% (13) |
2 |
18.6% (8) |
0 |
14.2% (25) |
2 |
0.560 |
1.000 |
0.563 |
Salicylate sensitivity, Ever ‡ |
18.5% (5) |
0 |
33.3% (30) |
2 |
18.6% (8) |
0 |
27.8% (49) |
2 |
0.140 |
1.000 |
0.307 |
ABPA, Ever ‡ |
14.8% (4) |
0 |
12.2% (11) |
2 |
14.0% (6) |
0 |
5.2% (9) |
4 |
0.746 |
1.000 |
0.079 |
Sulphite sensitivity, Ever ‡ |
7.4% (2) |
0 |
7.8% (7) |
2 |
11.6% (5) |
0 |
7.4% (13) |
3 |
1.000 |
0.699 |
1.000 |
COPD, Ever ‡ |
7.4% (2) |
0 |
6.7% (6) |
2 |
9.3% (4) |
0 |
10.8% (19) |
2 |
1.000 |
1.000 |
0.746 |
Nasal polyps, Ever ‡ |
24% (6) |
2 |
20.9% (18) |
6 |
37.5%
(15) |
3 |
19% (31) |
15 |
0.743 |
0.258 |
0.591 |
Nasal (polyps / sinus) surgery, Ever ‡ |
32% (8) |
2 |
31.3%
(26) |
13 |
35.7% (15) |
1 |
19.3% (31) |
17 |
0.949 |
0.757 |
0.145 |
Urticaria or Angioedema, Ever ‡ |
7.4% (2) |
0 |
13.3% (12) |
2 |
7.0% (3) |
0 |
6.8% (12) |
2 |
0.517 |
1.000 |
1.000 |
OSA, Ever ‡ |
11.1% (3) |
0 |
4.4% (4) |
2 |
4.7% (2) |
0 |
11.5% (20) |
4 |
0.350 |
0.367 |
1.000 |
Eczema, Ever ‡ |
25.9% (7) |
0 |
33.0% (30) |
1 |
25.6% (11) |
0 |
21.6% (38) |
2 |
0.489 |
1.000 |
0.614 |